Stimulants for the Control of Hedonic Appetite
- 1Sydney Medical School Nepean, The University of Sydney, Penrith, NSW, Australia
- 2Charles Perkins Centre Nepean, The University of Sydney, Penrith, NSW, Australia
The focus of this paper is treatment of obesity in relation to the management of hedonic appetite. Obesity is a complex condition which may be potentiated by excessive reward seeking in combination with executive functioning deficits that impair cognitive control of behavior. Stimulant medications address both reward deficiency and enhance motivation, as well as suppressing appetite. They have long been recognized to be effective for treating obesity. However, stimulants can be abused for their euphoric effect. They induce euphoria via the same neural pathway that underlies their therapeutic effect in obesity. For this reason they have generally not been endorsed for use in obesity. Among the stimulants, only phentermine (either alone or in combination with topiramate) and bupropion (which has stimulant-like properties and is used in combination with naltrexone), are approved by the United States Food and Drug Administration (FDA) for obesity, although dexamphetamine and methylpenidate are approved and widely used for treating attention deficit hyperactivity disorder (ADHD) in adults and children. Experience gained over many years in the treatment of ADHD demonstrates that with careful dose titration, stimulants can be used safely. In obesity, improvement in mood and executive functioning could assist with the lifestyle changes necessary for weight control, acting synergistically with appetite suppression. The obesity crisis has reached the stage that strong consideration should be given to adequate utilization of this effective and inexpensive class of drug.
The obesity epidemic has been attributed to the easy availability of high energy, palatable foods, together with an increasingly sedentary lifestyle. The solution to obesity should be a simple matter of balancing energy intake to requirement, but unfortunately this approach has had limited success and the prevalence of obesity continues to rise. Treatment of obesity has a cost, but could result in massive savings via long-term disease prevention.
The costs of obesity include the costs of treating the medical complications, the days of work missed and disability payments. The three main treatment modalities are lifestyle interventions, bariatric surgery or medication. A variety of psychological treatments have been trialed for assisting with making the required lifestyle changes (McElroy et al., 2015a). Success with lifestyle intervention depends on the individual's motivation and many cannot sustain the effort (Grodstein et al., 1996), limiting the cost-effectiveness of this modality. Bariatric surgery has the drawbacks of expense and surgical complications (Dixon, 2014), with ongoing costs of supplements to prevent nutritional deficiencies (Lopes et al., 2015). However, it has been calculated that the cost of surgery can be offset by savings in medication costs within 2–7 years, with those with existing obesity complications having the potential for the greatest savings (Lopes et al., 2015). Using more complex modeling, bariatric surgery appears highly cost-effective, with an average gain of 2.9 years of health at a relatively low cost of $9000 per year (Michaud et al., 2012). The benefits are less clear for medication as outcomes can be more variable. However, pharmacological treatment to help make necessary lifestyle changes more achievable would appear an attractive option, particularly if used as an early intervention. This would potentially involve more treatment-years and result in more modest benefits to a greater number of people. The cost-effectiveness of such treatment would be highly dependent on the cost of the drug. The cost of developing a new drug has been estimated at $2.6 billion (Avorn, 2015), which has to be recovered before the patent expires. This gives a substantial economic advantage to generic prescribing of older drugs.
One main target of pharmacotherapy is appetite suppression. Appetite control may be considered to have two components; homeostatic and hedonic. The homeostatic component has the essential function to maintain daily energy requirement for sustaining bodily functions such as body temperature, circulation, breathing, and the energy required for movement. Gut hormones like cholecystokinin, ghrelin, glucagon-like peptide-1, and peptide YY regulate the inclination to feed, having an immediate effect on sensations of hunger or satiety (Cummings and Overduin, 2007). Leptin reflects fat mass and acts over a longer time-frame to suppress the appetite as fat stores increase (Saad et al., 1998). Insulin, glucagon-like peptide-1, and cortisol have a regulatory role in energy balance and utilization (Osto et al., 2007). The hormonal homeostatic mechanisms adjust in response to weight loss with changes that increase the appetite and promote weight regain (Sumithran et al., 2011). However, eating is not simply a matter of meeting daily energy requirements but is also associated with pleasure. This leads to an additional hedonic drive to eat.
Hedonic appetite may be considered as a continuum, extending from the normal situation of individuals enjoying some foods more than others, through comfort eating which may occur when the mood is low, to the final extreme situation in which an individual appears to be addicted to food as to a drug of addiction.
The hedonic component of appetite is mediated by central reward mechanisms and has the ability to override homeostatic satiety mechanisms (Volkow et al., 2008). The enjoyment associated with eating is attributed to activation of the dopamine mediated reward pathway in the limbic region of the brain (Wang et al., 2009; DiLeone et al., 2012). The endocannabinoid and opioid systems are also involved in central appetite control, relating to food palatability, and interacting with mesolimbic reward pathway and reinforcing the motivation for food seeking (Volkow et al., 2008). The mesolimbic pathway communicates with the nucleus accumbens, which is involved in reward and appetite control. Wang et al. have shown reduced dopamine D2 receptor density in individuals with obesity (Wang et al., 2001). Although the resulting decreased dopaminergic activity could explain vulnerability to obesity, such that more food is required to obtain satisfaction (D'Addario et al., 2014), overeating of palatable food may itself lead to a reduction in the D2 receptors and promote compulsive eating (DiLeone et al., 2012). This suggests that a blunting of the reward mechanisms and associated desire for highly palatable food may be both a cause and a consequence of obesity. A similar situation pertains with drugs of abuse which may initially be taken for pleasure, subsequently progressing to craving, and diminished satisfaction due to desensitization of the reward mechanisms (Volkow et al., 2008). In each case the repetition leads to similar changes in the reward circuitry and associated reductions in the experience of pleasure for other activities, together with conditioning to stimulus related cues and compulsive consumption (Kenny et al., 2013).
The above mechanisms suggest that the enjoyment of palatable food may be pursued to excess, ultimately developing into a self-perpetuating cycle of craving and compulsive eating that is independent of hunger and which may manifest as binge eating (Ziauddeen et al., 2012; Gautron et al., 2015). This end-point may have contributing factors such as individual susceptibility (perhaps associated with low D2 receptors) and environmental factors (such as food availability) and lack of enjoyment or reward from other facets of life. An observational study showing that individuals who suffer from obesity may be prone to addiction (Reslan et al., 2014) supports the notion of a common susceptibility. The idea of obesity as an addiction is not new. The German word for obesity is “fettsucht” or “fat addiction.” Of course, putative food addiction differs from addiction to drugs as food is essential to life and there is no chemical withdrawal syndrome (Ziauddeen et al., 2012).
Although eating excessively for pleasure may progress to dissatisfaction, craving, and possible food addiction, this does not always happen. It has been suggested that some individuals may have under activity of their intrinsic reward mechanisms, resulting in reward seeking behavior that can be excessive and maladaptive. This has been termed reward deficiency syndrome (Downs et al., 2013). Dissatisfaction associated with a state of reward deficiency could be associated with low mood, which the individual might address with comfort eating. This could underpin the known association of obesity with depression (Dawes et al., 2016). This process could occur at a subtle level, with imperceptible discrepancies in the balance between energy intake and utilization over time leading to obesity.
This sensation of reward associated with food and other pleasurable stimuli is important for motivating animals to fulfill the basic functions that are necessary for the survival of the individual and the species. At a more subtle level, experiencing adequate satisfaction in the daily tasks of life helps to maintain a positive mood and outlook (Catalino and Fredrickson, 2011). Therefore, eating may be a strategy for mood regulation, with food restriction resulting in irritability.
Excessive hedonic appetite may be overcome by the executive functions of the prefrontal cortex exerting behavioral control for curbing disinhibited eating. This requires consistent motivation. Individuals lacking sufficient executive control may find it harder to combat obesity, due to their greater difficulty in making decisions that involve delaying gratification (Davis et al., 2010). This has been supported by a study that showed lower levels of activation of the prefrontal cortex in response to food in obese non-dieters when compared to successful dieters (DelParigi et al., 2007). Individuals with obesity could therefore be excessively reward seeking and they could also have deficits in the executive functions associated with motivation and cognitive control of behavior. However, as with the reward mechanisms, obesity can itself lead to impaired executive functioning and behavioral control. One obvious manifestation of this is in the repeated relapses that may follow well-reasoned decisions to keep to a diet (Volkow et al., 2016).
Similar reward and executive functioning deficits also typify ADHD (Poulton and Nanan, 2014), perhaps the main difference being that in obesity the reward seeking and executive functioning deficits, such as impulsive behavior and poor motivation, result in excessive food intake. In both conditions these two types of predisposing deficit would be summative in their effects.
Implications for Therapy—Stimulants
If an important biological mechanism is deficient to the extent that health is compromised, it is logical to try to treat the deficiency medically, targeting the pathways involved. Stimulants activate reward mechanisms by interacting with amine transporter systems, decreasing the synaptic reuptake of dopamine and noradrenaline (Madras et al., 2005), and to a lesser extent serotonin (Kuczenski and Segal, 1997) so that neurotransmission is enhanced. This results in mundane tasks appearing more rewarding (Volkow et al., 2004). Stimulants are also associated with appetite suppression, which correlates with the increased activity of the mesolimbic reward pathway and elevated extracellular dopamine the nucleus accumbens (Rowley et al., 2000). Therefore, stimulants address the reward deficit, which may rectify the compulsion to eat excessively and could also explain their positive effect on mood (Martin et al., 1971). However, stimulants have the additional effect of a dose-related improvement in executive functioning, hence their value in ADHD. It has been shown with methylphenidate that this improvement rises to a maximum and then declines once the optimal dose has been exceeded (Gamo et al., 2010). When treated with stimulants, children with ADHD are able to concentrate more consistently and are more efficient at task completion (MTA Cooperative Group, 1999). They are also more able to think rationally and consider the consequences of their actions.
The ability of the stimulants to target both the reward deficiency and the executive functioning deficits suggests that they are a logical treatment for obesity. At higher doses stimulants are associated with adverse effects on mood, progressing to nervousness, depression and emotional irritability, with reversible paranoia, and psychosis developing with further dose increases (Griffith et al., 1972). Stimulants are also associated with elevations in heart rate and blood pressure due to their sympathomimetic effects, which limits their use in individuals with cardiovascular disease (Stiefel and Besag, 2010). The practice of dose titration to maximize behavioral improvement and minimize adverse effects may explain their safety record in the treatment of ADHD (Merkel, 2010).
Although under activity of the reward pathway can lead to dissatisfaction and low mood, too much stimulation can be addictive and stimulants are recognized as drugs of abuse. The ability of stimulants to increase extracellular dopamine correlates not only with their therapeutic effect in ADHD and obesity but also with their ability to induce euphoria, which can be addictive (Volkow and Swanson, 2003). The reinforcing sensation of euphoria correlates with a rapid rate of dopamine receptor occupancy. As euphoria is dependent on the rate of absorption rather than the actual dose of stimulant, a dose of methylphenidate that might be therapeutic for oral administration, when given intranasally can produce euphoria comparable to that obtained using cocaine (Volkow and Swanson, 2003). Among the stimulants, methamphetamine is the most addictive as it rapidly accumulates in the brain, inducing euphoria even when taken orally (Fowler et al., 2008).
The first stimulant to be endorsed by the FDA for the treatment of obesity was methamphetamine in 1947 (United States Food and Drug Administration, 2012). In the 1950s and 1960s dexamphetamine was widely prescribed for a range of problems including obesity, depression, and poor motivation (Kiloh and Brandon, 1962). Although it was recognized that it might occasionally be taken as a habit to restore confidence it was generally considered safe even for long-term use (Editorial, BMJ, 1955). However, it came to light that some people were abusing dexamphetamine and had been fraudulently obtaining multiple prescriptions and having them dispensed by different pharmacies (Kiloh and Brandon, 1962). A few were admitted to hospital with psychosis and malnutrition, experiencing depression on drug withdrawal. Then the opinion suddenly turned against the stimulants for the treatment of obesity (United States Food and Drug Administration, 2012). Despite this, the stimulant phentermine has continued to be licensed for short term use in obesity and in combination with the anticonvulsant topiramate for long term use. Furthermore, bupropion, a drug used for treating depression and nicotine addiction, which has many similarities to the stimulants in its clinical effects, was licensed for treatment of obesity in combination with naltrexone in 2014 (United States Food and Drug Administration, 2014). Therefore, despite a widespread view that the use of stimulants for obesity is inappropriate, medications that appear remarkably similar in their effects and in their abuse potential are still being used. The use of the opiates for pain relief demonstrates that drugs that are highly addictive can be used therapeutically provided there are adequate safeguards. Similarly, the stimulants have continued to be prescribed for individuals with ADHD, a condition with recognized susceptibility to risky behavior including substance abuse (Molina et al., 2013).
The two main arguments against the stimulants is their abuse potential and their apparent loss of efficacy with time, once a new steady state has been reached after the initial weight loss. For example, the effect that stimulants have for enhancing reward could lead to inappropriate use, or potentiate addictive behavior or compulsions such as binge eating. However, lisdexamfetamine, a pro-drug for dexamphetamine, has been shown to be effective for reducing binge eating (McElroy et al., 2015b). Oral administration also reduces the risk as it limits the potential for euphoria and increases the probability of adverse gastrointestinal side effects such as nausea and fullness, which might be exacerbated by eating (DiLeone et al., 2012). Furthermore, stimulants are not associated with a physical withdrawal syndrome that promotes continuous use. Although stimulant abuse is a particular concern for people with risk factors for addiction, one very important distinction between individuals with obesity and those who have abused drugs is that food addiction does not involve any illegal activity. Therefore, such people could have strong reservations for using illegal or dishonest means for acquiring drugs.
When considering the advantages and disadvantages of the stimulants as outlined above, we consider the most appropriate way to use the stimulants in obesity would be to prescribe for a restricted period only, focusing on the beneficial effects on mood and motivation while establishing the lifestyle changes necessary for weight control, rather than encouraging reliance on the appetite suppression. This would also limit the potential for abuse and adverse long-term cardiovascular effects.
Psychotropic Effects of Drugs Developed for Obesity
Drugs that target hedonic appetite often have actions comparable to the stimulants on mood, motivation, and blood pressure, suggesting a comparable mode of action (Table 1). However, the beneficial psychotropic effects have generally been neglected and instead of dose optimization, studies have tended to randomize participants to fixed doses of active drug or placebo (Munro et al., 1968; Astrup et al., 2008). This methodology means that for some the dose will be too low, while others may have adverse effects on mood due to the dose being excessive. Poor understanding of the need for individual dose titration has resulted in drugs being attributed adverse psychiatric side effects. Given the complexities of the actions of these drugs and their varying affinities for the different neurotransmitter systems, the most practical way to determine the correct dose is by titration to the clinical effects. Titration works well in ADHD where the aim is to improve the functional deficits. Even in obesity there is often scope for improvement in mood and motivation and in our research we have found dose titration possible using adverse effects on mood as an indication for dose reduction (Poulton et al., 2015). Therefore, with correct use the psychotropic effects could have the potential to assist with the lifestyle changes that are vital for weight control. It is important for physicians to understand how best to use these medications (Fujioka, 2015).
Table 1. Drugs that are approved or have been trialed for the treatment of obesity and their psychotropic effects.
Phentermine has similarities with dexamphetamine in that at low dose a beneficial effect on mood has been observed while higher doses can induce hostility and anger (Brauer et al., 1996). It may be inferred that phentermine, as a stimulant, will lead to dose-related improvements in executive functioning (Gamo et al., 2010) and it has been used effectively for treating ADHD (Rothman, 1996). Although phentermine is considered less addictive than dexamphetamine (Griffiths et al., 1978), it is important to compare its effects at bioequivalent doses. Animal studies have shown that phentermine and dexamphetamine at equipotent doses for appetite suppression are associated with comparable levels of dopamine elevation in the nucleus accumbens (Rowley et al., 2000). Phentermine is generally used in a fixed dose regimen (Munro et al., 1968). It is now available in America in combination with topiramate (United States Food and Drug Administration, 2012; Alfaris et al., 2015) although marketing authority for this combination (Qsymia) was refused by the European Medicines Agency (European Medicines Agency, 2013). This combination uses lower doses of each drug than would be used with either drug given as monotherapy (Alfaris et al., 2015; British National Formulary, 2015). Phentermine is still available in the United Kingdom but is not officially recommended for use in obesity (Kumar and Aronne, 2015).
Topiramate is an anticonvulsant and is associated with sedation and dose related cognitive impairment, causing difficulties with memory and concentration at higher doses (Bray et al., 2003). At low dose it can lead to improvement in mood disorders but at higher doses can be associated with depression, aggression, and psychosis (Besag, 2004). Its mode of action in obesity is unclear, although there may be scope for dose titration to maximize the favorable effect on mood.
Bupropion is classified as a substituted cathinone, a class of drug that acts as a central nervous system stimulant as it increases the synaptic concentrations of catecholamines by inhibiting reuptake and enhancing their release (Paillet-Loilier et al., 2014). Experimentally in mice bupropion has a similar profile of dopamine related behavioral effects to methamphetamine, being rewarding (reinforcing) at lower doses and causing hyperlocomotion at higher doses (Mori et al., 2013). Interestingly, a study using bupropion for treating obesity documented weight loss with minimal effects on mood or behavior (Anderson et al., 2002), suggesting a low risk of adverse psychotropic effects. Bupropion can improve executive functioning (working memory and sustained attention; Perkins et al., 2013) and has been used for treating ADHD with comparable efficacy to methylphenidate. It has abuse potential, particularly when taken intranasally (Hilliard et al., 2013) and can cause a reversible psychosis (Javelot et al., 2010).
Bupropion is used for obesity in combination with naltrexone (Greenway et al., 2009) a mu opioid receptor antagonist that is used in the treatment of addiction to a range of substances including opiates, nicotine, alcohol and amphetamines as it reduces craving (Woody, 2014). Both bupropion and naltrexone are associated with weight loss and together their effects appear to be synergistic (Greenway et al., 2009). This combination (Contrave) was approved by the FDA for chronic weight management in 2014 (United States Food and Drug Administration, 2014).
Tesofensine is a drug that showed efficacy but was abandoned because it caused hypertension (Astrup et al., 2008). Like the stimulants, it blocks the reuptake of dopamine, noradrenaline, and serotonin. Effects on behavior and mood were noted in phase-II studies, with increased activity at all doses and mood changes, particularly at higher doses, including mood elevation and also anger and hostility. That these effects are likely to be dopaminergic is supported by positron emission tomography showing blockade of the dopamine transporter leading to up-regulation of the dopamine pathway (Appel et al., 2014). It can be speculated that as elevated blood pressure was predictable from its mode of action, this might have been managed with lower doses and a more flexible dosing regimen.
Cannibinoid Type 1 Receptor Blockers Rimonabant and Taranabant
Rimobanant initially appeared promising as a treatment for obesity as it was associated with improvement in cardiometabolic risk factors that appeared to be in excess of the improvement expected for the degree of weight loss (Nissen et al., 2008). Despite the psychiatric side effects of mood alteration, the drug was approved and marketed. However, once it was being used in greater numbers an association with suicide was observed and all trials were terminated (Topol et al., 2010; McElroy et al., 2015c).
Taranabant is closely related to rimonabant. When rimonabant was withdrawn, all further development of taranabant was terminated (Aronne et al., 2010). In phase-II trials that involved randomization to fixed doses of drug it was noted that psychiatric side effects were the commonest reason for study attrition (Proietto et al., 2010). Anger and hostility were seen at all doses. At the lowest dose there was increased vigor-activity; depression-dejection was seen on the highest dose. These apparently dopaminergic effects may be due to synergy of the dopamine and endocannibinoid pathway (Despres et al., 2005).
Physicians treating obesity need to understand and appreciate the psychotropic properties of anorexigenic medications, so that treatment can be optimized. The psychiatric side effects that have plagued many efficacy studies might actually be evidence of their mode of action and therefore their efficacy (Astrup et al., 2008; Proietto et al., 2010). This misclassification of the associations of therapeutic efficacy may be sabotaging an important line of drug development. The potential for abuse of drugs with dopaminergic effects is a serious concern but does not preclude their use in ADHD. Indeed there is no clearly apparent logical reason why dexamphetamine is used for treating ADHD while phentermine has been retained for obesity, which raises the question of whether this was simply an accident of history. Ongoing research in our group is examining the effects of dexamphetamine for treating obesity (Poulton et al., 2015). We suggest that the prejudice against the stimulants for treating obesity is perhaps misplaced and favors surgery and new drug development. Meanwhile, in the absence of cheap, effective and accessible treatments the obesity epidemic shows little sign of abating.
Idea was conceived by AP and RN, who together wrote the first draft. The paper was revised with the input from EH and BC. All authors approved the final version.
This paper was unfunded, other than the publication fee, paid by The Nepean Hospital Department of Endocrinology Trust Fund.
Conflict of Interest Statement
AP reports personal fees and non-financial support from Shire, outside the submitted work and shares in GSK. BC reports personal fees from Novartis, MSD and Astra Zeneca and non-financial support from Novartis, outside the submitted work. RN reports being director of Vascular Access Technologies Pty Ltd and being listed as one of 6 co-investigators on a provisional patent application lodged through the University of Sydney for a portable automated cannulation device.
The other author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Alfaris, N., Minnick, A. M., Hopkins, C. M., Berkowitz, R. I., and Wadden, T. A. (2015). Combination phentermine and topiramate extended release in the management of obesity. Expert Opin. Pharmacother. 16, 1263–1274. doi: 10.1517/14656566.2015.1041505
Anderson, J. W., Greenway, F. L., Fujioka, K., Gadde, K. M., McKenney, J., and O'Neil, P. M. (2002). Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. Obes. Res. 10, 633–641. doi: 10.1038/oby.2002.86
Appel, L., Bergstrom, M., Buus Lassen, J., and Langstrom, B. (2014). Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: dopamine transporter occupancy as measured by PET. Eur. Neuropsychopharmacol. 24, 251–261. doi: 10.1016/j.euroneuro.2013.10.007
Aronne, L. J., Tonstad, S., Moreno, M., Gantz, I., Erondu, N., Suryawanshi, S., et al. (2010). A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. Int. J. Obes. 34, 919–935. doi: 10.1038/ijo.2010.21
Astrup, A., Madsbad, S., Breum, L., Jensen, T. J., Kroustrup, J. P., and Larsen, T. M. (2008). Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 372, 1906–1913. doi: 10.1016/S0140-6736(08)61525-1
Brauer, L. H., Johanson, C. E., Schuster, C. R., Rothman, R. B., and de Wit, H. (1996). Evaluation of phentermine and fenfluramine, alone and in combination, in normal, healthy volunteers. Neuropsychopharmacology 14, 233–241. doi: 10.1016/0893-133X(95)00113-R
Bray, G. A., Hollander, P., Klein, S., Kushner, R., Levy, B., Fitchet, M., et al. (2003). A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes. Res. 11, 722–733. doi: 10.1038/oby.2003.102
D'Addario, C., Micioni Di Bonaventura, M. V., Pucci, M., Romano, A., Gaetani, S., Ciccocioppo, R., et al. (2014). Endocannabinoid signaling and food addiction. Neurosci. Biobehav. Rev. 47, 203–224. doi: 10.1016/j.neubiorev.2014.08.008
Davis, C., Patte, K., Curtis, C., and Reid, C. (2010). Immediate pleasures and future consequences. A neuropsychological study of binge eating and obesity. Appetite 54, 208–213. doi: 10.1016/j.appet.2009.11.002
Dawes, A. J., Maggard-Gibbons, M., Maher, A. R., Booth, M. J., Miake-Lye, I., Beroes, J. M., et al. (2016). Mental health conditions among patients seeking and undergoing bariatric surgery: a meta-analysis. JAMA 315, 150–163. doi: 10.1001/jama.2015.18118
DelParigi, A., Chen, K., Salbe, A. D., Hill, J. O., Wing, R. R., Reiman, E. M., et al. (2007). Successful dieters have increased neural activity in cortical areas involved in the control of behavior. Int. J. Obes. 31, 440–448. doi: 10.1038/sj.ijo.0803431
Despres, J. P., Golay, A., and Sjostrom, L. (2005). Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353, 2121–2134. doi: 10.1056/NEJMoa044537
DiLeone, R. J., Taylor, J. R., and Picciotto, M. R. (2012). The drive to eat: comparisons and distinctions between mechanisms of food reward and drug addiction. Nat. Neurosci. 15, 1330–1335. doi: 10.1038/nn.3202
Downs, B., Oscar-Berman, M., Waite, R., Madigan, M., Giordano, J., Beley, T., et al. (2013). Have we hatched the addiction egg: reward deficiency syndrome solution system. J. Genet. Syndr. Gene Ther. 4, 14318. doi: 10.4172/2157-7412.1000136
Fowler, J. S., Volkow, N. D., Logan, J., Alexoff, D., Telang, F., Wang, G. J., et al. (2008). Fast uptake and long-lasting binding of methamphetamine in the human brain: comparison with cocaine. Neuroimage 43, 756–763. doi: 10.1016/j.neuroimage.2008.07.020
Gamo, N. J., Wang, M., and Arnsten, A. F. (2010). Methylphenidate and atomoxetine enhance prefrontal function through alpha2-adrenergic and dopamine D1 receptors. J. Am. Acad. Child Adolesc. Psychiatry 49, 1011–1023. doi: 10.1016/j.jaac.2010.06.015
Greenway, F. L., Dunayevich, E., Tollefson, G., Erickson, J., Guttadauria, M., Fujioka, K., et al. (2009). Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J. Clin. Endocrinol. Metab. 94, 4898–4906. doi: 10.1210/jc.2009-1350
Griffith, J. D., Cavanaugh, J., Held, J., and Oates, J. A. (1972). Dextroamphetamine. Evaluation of psychomimetic properties in man. Arch. Gen. Psychiatry 26, 97–100. doi: 10.1001/archpsyc.1972.01750200001001
Griffiths, R. R., Brady, J. V., and Snell, J. D. (1978). Relationship between anorectic and reinforcing properties of appetite suppressant drugs: implications for assessment of abuse liability. Biol. Psychiatry 13, 283–290.
Grodstein, F., Levine, R., Troy, L., Spencer, T., Colditz, G. A., and Stampfer, M. J. (1996). Three-year follow-up of participants in a commercial weight loss program. Can you keep it off? Arch. Intern. Med. 156, 1302–1306. doi: 10.1001/archinte.1996.00440110068009
Hilliard, W. T., Barloon, L., Farley, P., Penn, J. V., and Koranek, A. (2013). Bupropion diversion and misuse in the correctional facility. J. Correct Health Care 19, 211–217. doi: 10.1177/1078345813486448
Javelot, T., Javelot, H., Baratta, A., Weiner, L., Messaoudi, M., and Lemoine, P. (2010). [Acute psychotic disorders related to bupropion: review of the literature]. Encephale 36, 461–471. doi: 10.1016/j.encep.2010.01.005
Kenny, P. J., Voren, G., and Johnson, P. M. (2013). Dopamine D2 receptors and striatopallidal transmission in addiction and obesity. Curr. Opin. Neurobiol. 23, 535–538. doi: 10.1016/j.conb.2013.04.012
Kuczenski, R., and Segal, D. S. (1997). Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J. Neurochem. 68, 2032–2037. doi: 10.1046/j.1471-4159.1997.68052032.x
Lopes, E. C., Heineck, I., Athaydes, G., Meinhardt, N. G., Souto, K. E., and Stein, A. T. (2015). Is bariatric surgery effective in reducing comorbidities and drug costs? A systematic review and meta-analysis. Obes. Surg. 25, 1741–1749. doi: 10.1007/s11695-015-1777-5
Martin, W. R., Sloan, J. W., Sapira, J. D., and Jasinski, D. R. (1971). Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin. Pharmacol. Ther. 12, 245–258. doi: 10.1002/cpt1971122part1245
McElroy, S. L., Guerdjikova, A. I., Mori, N., and Keck, P. E., Jr. (2015c). Psychopharmacologic treatment of eating disorders: emerging findings. Curr. Psychiatry Rep. 17, 35. doi: 10.1007/s11920-015-0573-1
McElroy, S. L., Hudson, J. I., Mitchell, J. E., Wilfley, D., Ferreira-Cornwell, M. C., Gao, J., et al. (2015b). Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry 72, 235–246. doi: 10.1001/jamapsychiatry.2014.2162
Michaud, P. C., Goldman, D. P., Lakdawalla, D. N., Zheng, Y., and Gailey, A. H. (2012). The value of medical and pharmaceutical interventions for reducing obesity. J. Health Econ. 31, 630–643. doi: 10.1016/j.jhealeco.2012.04.006
Molina, B. S., Hinshaw, S. P., Eugene Arnold, L., Swanson, J. M., Pelham, W. E., Hechtman, L., et al. (2013). Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. J. Am. Acad. Child Adolesc. Psychiatry 52, 250–263. doi: 10.1016/j.jaac.2012.12.014
Mori, T., Shibasaki, M., Ogawa, Y., Hokazono, M., Wang, T. C., Rahmadi, M., et al. (2013). Comparison of the behavioral effects of bupropion and psychostimulants. Eur. J. Pharmacol. 718, 370–375. doi: 10.1016/j.ejphar.2013.07.046
MTA Cooperative Group (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry 56, 1073–1086. doi: 10.1001/archpsyc.56.12.1073
Nissen, S. E., Nicholls, S. J., Wolski, K., Rodes-Cabau, J., Cannon, C. P., Deanfield, J. E., et al. (2008). Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 299, 1547–1560. doi: 10.1001/jama.299.13.1547
Osto, M., Wielinga, P. Y., Alder, B., Walser, N., and Lutz, T. A. (2007). Modulation of the satiating effect of amylin by central ghrelin, leptin and insulin. Physiol. Behav. 91, 566–572. doi: 10.1016/j.physbeh.2007.03.017
Paillet-Loilier, M., Cesbron, A., Le Boisselier, R., Bourgine, J., and Debruyne, D. (2014). Emerging drugs of abuse: current perspectives on substituted cathinones. Subst. Abuse Rehabil. 5, 37–52. doi: 10.2147/SAR.S37257
Perkins, K. A., Karelitz, J. L., Jao, N. C., Gur, R. C., and Lerman, C. (2013). Effects of bupropion on cognitive performance during initial tobacco abstinence. Drug Alcohol Depend. 133, 283–286. doi: 10.1016/j.drugalcdep.2013.05.003
Poulton, A., and Nanan, R. (2014). The attention deficit hyperactivity disorder phenotype as a summation of deficits in executive functioning and reward sensitivity: does this explain its relationship with oppositional defiant disorder? Australas. Psychiatry 22, 174–178. doi: 10.1177/1039856213517949
Poulton, A. S., Hibbert, E. J., Champion, B. L., Cook, T. L., Alais, D., and Coulshed, D. S. (2015). Piloting a new approach to the treatment of obesity using dexamphetamine. Front. Endocrinol. 6:14. doi: 10.3389/fendo.2015.00014
Proietto, J., Rissanen, A., Harp, J. B., Erondu, N., Yu, Q., Suryawanshi, S., et al. (2010). A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study. Int. J. Obes. 34, 1243–1254. doi: 10.1038/ijo.2010.38
Rowley, H. L., Butler, S. A., Prow, M. R., Dykes, S. G., Aspley, S., Kilpatrick, I. C., et al. (2000). Comparison of the effects of sibutramine and other weight-modifying drugs on extracellular dopamine in the nucleus accumbens of freely moving rats. Synapse 38, 167–176. doi: 10.1002/1098-2396(200011)38:2<167::AID-SYN8>3.0.CO;2-W
Saad, M. F., Riad-Gabriel, M. G., Khan, A., Sharma, A., Michael, R., Jinagouda, S. D., et al. (1998). Diurnal and ultradian rhythmicity of plasma leptin: effects of gender and adiposity. J. Clin. Endocrinol. Metab. 83, 453–459. doi: 10.1210/jc.83.2.453
Stiefel, G., and Besag, F. M. (2010). Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder. Drug Saf. 33, 821–842. doi: 10.2165/11536380-000000000-00000
Sumithran, P., Prendergast, L. A., Delbridge, E., Purcell, K., Shulkes, A., Kriketos, A., et al. (2011). Long-term persistence of hormonal adaptations to weight loss. N. Engl. J. Med. 365, 1597–1604. doi: 10.1056/NEJMoa1105816
Topol, E. J., Bousser, M. G., Fox, K. A., Creager, M. A., Despres, J. P., Easton, J. D., et al. (2010). Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet 376, 517–523. doi: 10.1016/S0140-6736(10)60935-X
Volkow, N. D., and Swanson, J. M. (2003). Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am. J. Psychiatry 160, 1909–1918. doi: 10.1176/appi.ajp.160.11.1909
Volkow, N. D., Wang, G. J., Fowler, J. S., and Telang, F. (2008). Overlapping neuronal circuits in addiction and obesity: evidence of systems pathology. Philos. Trans. R. Soc. Lond. B Biol. Sci. 363, 3191–3200. doi: 10.1098/rstb.2008.0107
Volkow, N. D., Wang, G. J., Fowler, J. S., Telang, F., Maynard, L., Logan, J., et al. (2004). Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. Am. J. Psychiatry 161, 1173–1180. doi: 10.1176/appi.ajp.161.7.1173
Wang, G. J., Volkow, N. D., Thanos, P. K., and Fowler, J. S. (2009). Imaging of brain dopamine pathways: implications for understanding obesity. J. Addict. Med. 3, 8–18. doi: 10.1097/ADM.0b013e31819a86f7
Keywords: appetite suppressants, dexamphetamine, obesity, reward deficiency, phentermine, hedonic appetite
Citation: Poulton AS, Hibbert EJ, Champion BL and Nanan RKH (2016) Stimulants for the Control of Hedonic Appetite. Front. Pharmacol. 7:105. doi: 10.3389/fphar.2016.00105
Received: 18 December 2015; Accepted: 07 April 2016;
Published: 25 April 2016.
Edited by:Claudio Bucolo, University of Catania, Italy
Reviewed by:Adán Dagnino-Acosta, University Center for Biomedical Research/CONACYT Research Fellow-University of Colima, Mexico
Harriet Schellekens, University College Cork, Ireland
Aaron G. Roseberry, Georgia State University, USA
Copyright © 2016 Poulton, Hibbert, Champion and Nanan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Alison S. Poulton, email@example.com